Opus Genetics (NASDAQ:IRD – Get Free Report) and Atara Biotherapeutics (NASDAQ:ATRA – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations and valuation.
Analyst Ratings
This is a summary of current recommendations and price targets for Opus Genetics and Atara Biotherapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Opus Genetics | 1 | 1 | 15 | 1 | 2.89 |
| Atara Biotherapeutics | 1 | 1 | 1 | 1 | 2.50 |
Opus Genetics currently has a consensus target price of $11.92, suggesting a potential upside of 145.58%. Atara Biotherapeutics has a consensus target price of $9.50, suggesting a potential upside of 12.43%. Given Opus Genetics’ stronger consensus rating and higher possible upside, research analysts clearly believe Opus Genetics is more favorable than Atara Biotherapeutics.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Opus Genetics | $14.20 million | 28.26 | -$49.59 million | ($1.35) | -3.60 |
| Atara Biotherapeutics | $120.77 million | 0.70 | $32.69 million | ($1.18) | -7.16 |
Atara Biotherapeutics has higher revenue and earnings than Opus Genetics. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Opus Genetics and Atara Biotherapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Opus Genetics | -1,091.82% | -338.88% | -150.13% |
| Atara Biotherapeutics | -269.42% | -79.12% | -73.01% |
Risk and Volatility
Opus Genetics has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500. Comparatively, Atara Biotherapeutics has a beta of 0.1, meaning that its share price is 90% less volatile than the S&P 500.
Institutional and Insider Ownership
15.0% of Opus Genetics shares are owned by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are owned by institutional investors. 11.7% of Opus Genetics shares are owned by insiders. Comparatively, 41.2% of Atara Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
Atara Biotherapeutics beats Opus Genetics on 8 of the 14 factors compared between the two stocks.
About Opus Genetics
Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
Receive News & Ratings for Opus Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opus Genetics and related companies with MarketBeat.com's FREE daily email newsletter.
